CorVel combines a debt-free balance sheet and sticky claims technology with expanding AI and CERIS opportunities, but its premium valuation leaves returns dependent on sustained growth and disciplined execution.
Overview
CorVel provides technology-enabled claims administration and healthcare cost containment through Patient Management and Network Solutions, serving insurers, self-insured employers, TPAs, public agencies, and commercial health payors across all 50 states. Its CareMC® platform combines claims workflows with bill review, repricing, PPO, PBM, and CERIS payment-integrity services. **The investment case rests on an integrated platform with meaningful switching costs, expanding commercial-health reach, and automation that can improve margins.** In Q1 FY2027, revenue increased 10.7% to $259.9 million, gross margin rose 190 basis points to 26.1%, operating income grew 22.8% to $43.3 million, and diluted EPS rose 21.2% to $0.63; EPS included a $0.07 one-time CERIS contribution. The company ended the quarter with $255.9 million in cash and no debt. At $73.84 in late September 2026, shares traded at 33.0x TTM P/E and 19.2x EV/EBITDA, a premium that requires continued execution. The report’s probability-weighted five-year value is $112.86, with a 55% base case of $109.20. Near-term catalysts include enterprise TPA wins, additional carrier integrations, CERIS adoption, and broader AI workflow deployment.